Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Total Non-Current Liabilities (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $21.2 million as the latest value for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 33.56% to $21.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Mar 2026, up 33.56% year-over-year, with the annual reading at $18.7 million for FY2025, 12.84% up from the prior year.
  • Total Non-Current Liabilities for Q1 2026 was $21.2 million at Achieve Life Sciences, up from $18.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $21.9 million in Q2 2024, with the low at $4.2 million in Q4 2023.
  • Average Total Non-Current Liabilities over 4 years is $17.0 million, with a median of $17.8 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities surged 298.01% in 2024, then decreased 21.04% in 2025.
  • Achieve Life Sciences' Total Non-Current Liabilities stood at $4.2 million in 2023, then surged by 298.01% to $16.6 million in 2024, then increased by 12.84% to $18.7 million in 2025, then grew by 13.04% to $21.2 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Total Non-Current Liabilities are $21.2 million (Q1 2026), $18.7 million (Q4 2025), and $18.4 million (Q3 2025).